Eli Lilly and Company will present new clinical data across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid, Spain, from 23 to 27 October.
The presentations will cover investigational therapies and updated clinical findings in ovarian, lung, thyroid and breast cancers, including results from Phase 1, Phase 2 and Phase 3 studies.
One key presentation will feature the first Phase 1 data for sofetabart mipitecan, an investigational antibody-drug conjugate targeting folate receptor alpha (FRฮฑ), in combination with bevacizumab for patients with platinum-sensitive ovarian cancer. The findings will support the ongoing Phase 3 FRAmework-01 study.
Click here to join our WhatsApp channel here
Lilly will also present an updated analysis of olomorasib, an investigational KRAS G12C inhibitor, combined with chemotherapy and immunotherapy as a potential first-line treatment for advanced or metastatic KRAS G12C-mutant non-small cell lung cancer.
In thyroid cancer, updated Phase 3 LIBRETTO-531 results will compare selpercatinib with cabozantinib or vandetanib in patients with advanced RET-mutant medullary thyroid cancer who have not previously received a kinase inhibitor.
The programme will also include overall survival data from the Phase 3 postMONARCH trial, evaluating abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer whose disease progressed after previous CDK4/6 inhibitor and endocrine therapy treatment.
Also read: Saudi Medical Campaign Provides Free Eye Care to More Than 5,000 People in Bangladesh
“Lilly’s presentations at ESMO reflect both the breadth of our oncology portfolio and the focus behind it: following compelling science wherever it has the potential to change care,” said Jacob Van Naarden, executive vice president and president of Lilly
Oncology. “We’re especially encouraged by the data we’re sharing for sofetabart mipitecan in platinum-sensitive ovarian cancer, which build on what we’ve seen with this medicine in platinum-resistant disease and mark a critical step forward as we advance the ongoing Phase 3 FRAmework-01 study across both settings. Our updated first-line data for olomorasib in KRAS G12C-mutant lung cancer are very promising, with clinical activity and a safety profile consistent with earlier findings, which reinforce the importance of targeted therapy for patients from the outset of their treatment journey. Alongside new data in thyroid and breast cancers, these presentations represent meaningful momentum toward improving care for people with cancer.”
